NCT06843044View on ClinicalTrials.gov

Efficacy and Safety of Ranquilon in Patients With Anxiety Disorders Due to Neurasthenia and Adjustment Disorders

PHASE4RecruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

January 13, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
AnxietyNeurastheniaAdjustment Disorders
Interventions
DRUG

Ranquilon

1 mg tablets

DRUG

Afobazole

10 mg tablets

Trial Locations (6)

119571

RECRUITING

Unimed-C Jsc, Moscow

194156

RECRUITING

Aurora MedFort LLC, Saint Petersburg

196143

RECRUITING

"Limited Liability Company Research Center Eco-Safety", Saint Petersburg

410038

RECRUITING

Saratov City Psychoneurological Dispensary, Saratov

413090

RECRUITING

Engels Psychiatric Hospital State Health Care Institution of the Ministry of Health of the Saratov Region, Engel's

Unknown

RECRUITING

"Limited Liability Company Stepmed Clinic", Saint Petersburg

All Listed Sponsors
lead

Valenta Pharm JSC

INDUSTRY